Makassed General Hospital

The outcome of non-muscle invasive urinary bladder tumour at Makassed General Hospital

Imad El Hajjar
Department of surgery, Urology division
Introduction

• Most common malignancy of the urinary tract, the 7th most common cancer in men and the 17th in women\textsuperscript{1}

• Tobacco smoking is the most important risk factor, accounting for 50\% of cases\textsuperscript{2-3}

\textsuperscript{1}Ferlay J et al.\textit{Int. J. Cancer} 2010; 127:2893-2917.
\textsuperscript{3}Freedman ND et al. \textit{JAMA} 2011; 306:737–45.
Introduction

• 75% of newly diagnosed cases are non-muscle invasive and have a high rate of recurrence and progression despite local therapy. The remaining 25% present with muscle invasion\(^1\)\(^-\)\(^2\)

Objectives

- Document the outcome of non-muscle invasive urinary bladder tumour
- Provide data on epidemiology
- Evaluate the effect of treatment on patient quality of life
Materials and Methods

- Retrospective cohort study
- Makassed General Hospital
- From January 2009 to February 2015
- Total of 181 patients underwent TURBT
Data

- Age
- Gender
- Smoking
- Histology
- Recurrence
- Management
Materials and Methods

Inclusion criteria
- Pathologically confirmed non-muscle invasive bladder tumour (131 patients)

Exclusion criteria
- Pathologically confirmed muscle invasive urinary bladder tumour at first time resection (32 patients)
- Patients who lost follow-up during the first year of treatment (18 patients)
Materials and Methods

- Quality of life was assessed using the validated NCCN-FACT FBISI-18 (Version 2) questionnaire. This questionnaire is a general nonspecific tool that assesses QOL in bladder cancer patients.
Statistical analysis

- SPSS version 21 software
- Chi-square and ANOVA tests
- P-Values below 0.05 were considered statistically significant
Results
Age distribution of all bladder cancer cases by gender

122 patients (82%) are males
27 patients (18%) are females
Male to female ratio 4.5 to 1

86% found to be smokers
90% presented with hematuria
## Histological tumour characteristics

<table>
<thead>
<tr>
<th>Pathology result</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TCC</strong></td>
<td>146</td>
<td>98.0 %</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>3</td>
<td>2.0 %</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumour stage</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ta</strong></td>
<td>47</td>
<td>31.5 %</td>
</tr>
<tr>
<td><strong>T1</strong></td>
<td>102</td>
<td>68.5 %</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High</strong></td>
<td>41</td>
<td>27.5 %</td>
</tr>
<tr>
<td><strong>Low</strong></td>
<td>108</td>
<td>72.5 %</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumour size</th>
<th>Number</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&lt;3</strong></td>
<td>88</td>
<td>59.1 %</td>
</tr>
<tr>
<td><strong>=&gt;3</strong></td>
<td>61</td>
<td>40.9 %</td>
</tr>
</tbody>
</table>
Pie chart of patient’s management

- Active surveillance: 49%
- Intravesical BCG: 32%
- Radical cystectomy: 7%
- Patient refusal: 12%
Results

- Recurrence rate 28% with no statistical difference between age, sex, smoking, histological types, tumour grade and tumour size
- 84% of recurrent cases had tumour stage T1, in comparison to 58% in non-recurrent cases with significant p value of 0.007
- Among the recurrent cases, 70% of patients didn’t stop smoking
Tumour recurrence according to different treatment protocols

- Active surveillance: 88% cured, 12% recurred
- Intravesical BCG: 72% cured, 28% recurred
- Radical cystectomy: 100% cured
- Patient refusal: 0% cured, 100% recurred

*p value <0.0001*
## Univariate analysis for bladder cancer patients in different treatment groups

<table>
<thead>
<tr>
<th>Questionnaire item</th>
<th>Surveillance</th>
<th>BCG</th>
<th>Radical C</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical Disease Related Symptoms Scale</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pain</strong></td>
<td>0.31 (sd=0.52)</td>
<td>1.67 (sd=0.69)</td>
<td>3.22 (sd=0.44)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Weight loss</strong></td>
<td>0.12 (sd=0.33)</td>
<td>1.16 (sd=0.48)</td>
<td>3.22 (sd=0.44)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Trouble in urine control</strong></td>
<td>0.17 (sd=0.38)</td>
<td>1.81 (sd=0.71)</td>
<td>3.67 (sd=0.50)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>General weakness</strong></td>
<td>0.07 (sd=0.26)</td>
<td>1.16 (sd=0.48)</td>
<td>3.00 (sd=0.00)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Dizziness</strong></td>
<td>0.02 (sd=0.15)</td>
<td>1.13 (sd=0.45)</td>
<td>3.00 (sd=0.00)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Trouble in meeting family needs</strong></td>
<td>0.17 (sd=0.44)</td>
<td>1.42 (sd=0.71)</td>
<td>3.56 (sd=0.53)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Appetite</strong></td>
<td>3.95 (sd=0.22)</td>
<td>3.11 (sd=0.54)</td>
<td>1.56 (sd=0.53)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>(for men only) erection</strong></td>
<td>3.87 (sd=0.34)</td>
<td>3.02 (sd=0.98)</td>
<td>0.00 (sd=0.00)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Good sleeping</strong></td>
<td>3.83 (sd=0.38)</td>
<td>2.98 (sd=0.63)</td>
<td>1.90 (sd=0.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Emotional disease related Symptoms subscale</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Worry about the illness</strong></td>
<td>0.10 (sd=0.30)</td>
<td>1.63 (sd=0.63)</td>
<td>3.11 (sd=0.60)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td><strong>Sadness</strong></td>
<td>0.14 (sd=0.35)</td>
<td>1.50 (sd=0.64)</td>
<td>3.11 (sd=0.60)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
Univariate analysis for bladder cancer patients in different treatment groups

<table>
<thead>
<tr>
<th>Questionnaire item</th>
<th>Surveillance</th>
<th>BCG</th>
<th>Radical C</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nausea</td>
<td>0.02 (sd=0.15)</td>
<td>1.06 (sd=0.43)</td>
<td>2.44 (sd=0.53)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Lack of energy</td>
<td>0.10 (sd=0.30)</td>
<td>1.13 (sd=0.45)</td>
<td>2.89 (sd=0.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Feeling ill</td>
<td>0.05 (sd=0.22)</td>
<td>1.19 (sd=0.53)</td>
<td>2.78 (sd=0.44)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Bowels control</td>
<td>3.98 (sd=0.15)</td>
<td>3.72 (sd=0.70)</td>
<td>1.89 (sd=0.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Bothering from treatment side effects</td>
<td>0.12 (sd=0.40)</td>
<td>2.01 (sd=0.83)</td>
<td>3.33 (sd=0.50)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Enjoying life</td>
<td>3.95 (sd=0.22)</td>
<td>2.63 (sd=0.81)</td>
<td>1.11 (sd=0.33)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Satisfaction with quality of live</td>
<td>4.00 (sd=0.00)</td>
<td>2.77 (sd=0.94)</td>
<td>1.00 (sd=0.00)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>
Discussion
Discussion

• In Lebanon, incidence increased markedly in the past years\textsuperscript{1-2}, having the second highest rate worldwide after Belgium\textsuperscript{3}
• 86\% of our patients were smokers, which is markedly higher than internationally published data which account for approximately 50\% of cases

Unaware about smoking as a risk factor for urinary bladder tumour

58.4% for bladder cancer, 94.6% awareness for COPD, the 92% for heart disease, vascular problems and lung cancer³

This difference may be explained by delay in seeking medical advice in our community, leading to upstaging of tumour at presentation.

• Comparable to what was published by Sylvester et al, the recurrence rate was 26% for patients treated with adjuvant BCG
• The therapeutic benefit of BCG for T1G3 bladder cancer has been definitively established

Discussion

• Despite cystectomy provides the most definitive opportunity for cure and obviates the need for repeated intravesical therapies and simplifies follow-up\(^1\), Cystectomy have a detrimental impact on quality of life secondary to long-term changes in sexual, gastrointestinal, and genitourinary function

Discussion

• The health burden by urinary bladder cancer is likely to increase in the future, since rising urinary bladder cancer incidence rates are expected in developing countries mainly related to the pronounced and ongoing prevalence of smoking

Conclusion

• The outcome of non-muscle invasive urinary bladder tumour patients at Makassed General Hospital is comparable to internationally published data, regarding cure rate and recurrence rate.

• Counseling patients regarding the risk of tobacco is a role of urologists.

• Quality of life should be considered in treating urinary bladder tumour patients.
THANK YOU